Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06267274 · ClinicalTrials.gov registry record · Phase 1
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
A Phase 1 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Amneal Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 240
- Enrollment target
- 4
- Study locations
NCT06267274: Recruiting Phase 1 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Amneal Pharmaceuticals.
NCT06267274 is a Phase 1 study of Ocular Hypertension and Open Angle Glaucoma that is actively recruiting participants, run by Amneal Pharmaceuticals. The registered enrollment target is 240 participants, below the 274-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (12% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06267274, a Phase 1 study of Ocular Hypertension and Open Angle Glaucoma, is actively recruiting participants, sponsored by Amneal Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 240 participants
- Enrollment target
- 4
- Study locations
Study Summary
A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, clinical endpoint bioequivalence study
Conditions Studied
Interventions
- DRUG Bimatoprost Ophthalmic Solution, 0.01%
- DRUG LUMIGAN® (bimatoprost ophthalmic solution) 0.01%
Study Locations (4)
California
- West Coast Eye Institute - Bakersfield
- Eye Research Foundation - Newport Beach
Georgia
- Clayton Eye Research - Morrow
Texas
- Houston Eye Associates - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2025-05-01 |
| Phase | Phase 1 |
What NCT06267274 shows while recruiting
NCT06267274 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 274-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (12% lower).
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Bimatoprost Ophthalmic Solution, 0.01% is the first listed.
NCT06267274 reports a single indexed study location in California, Georgia, Texas.
Frequently Asked Questions
What is clinical trial NCT06267274 about?
NCT06267274 is a clinical study titled "A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes". A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, clinical endpoint bioequivalence study
What is the current status of trial NCT06267274?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2024-04-01. Estimated completion is 2025-05-01.
What conditions does trial NCT06267274 study?
This clinical trial studies the following conditions: Ocular Hypertension, Open Angle Glaucoma.
What interventions are being tested in trial NCT06267274?
The interventions under investigation include: Bimatoprost Ophthalmic Solution, 0.01% (DRUG), LUMIGAN® (bimatoprost ophthalmic solution) 0.01% (DRUG).
Who is sponsoring clinical trial NCT06267274?
This trial is sponsored by Amneal Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06267274 being conducted?
This trial has 4 study locations across California, Georgia, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06267274's enrollment target sits among peer trials
240 20th of 54 higher than 35 of 54 other Ocular Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ocular Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 1
-
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
ACTIVE NOT RECRUITING · Phase 1
-
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
ACTIVE NOT RECRUITING · Phase 1
-
Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma
COMPLETED · Phase 1
-
A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
COMPLETED · Phase 1
-
Safety and IOP-Lowering Effects of WB007
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI